[ad_1]
STATEN ISLAND, N.Y. – Another medication against high blood pressure has been added to a long list of recalls, as it could contain an impurity that can cause cancer, according to the FDA (Food and Drug Administration).
Macleods Pharmaceuticals Limited recalls a batch of 100 mg / 25 mg combination tablets of potassium and hydrochlorothiazide from Losartan, packaged in bottles of 90 tablets. The lot number is BLM715AJ, with an expiry date of July 2019.
Combined tablets are used to treat hypertensive and hypertensive patients with left ventricular hypertrophy.
The drug was recalled because it had an impurity known as N-nitrosodiethylamine, which was classified as a possible carcinogen to humans. This could lead to an increased risk of cancer in patients.
The chemical is usually found in very small amounts in certain foods, drinking water, air pollution and some industrial processes.
The FDA has indicated that Macleods Pharmaceuticals Limited has not received any reports of adverse events.
Patients taking this medication should continue to take their medication because the risk of harm to the patient's health could be higher if the treatment was stopped immediately without further treatment, according to the FDA.
The FDA has announced various recalls since last July. Consumers can view the FDA's recall announcement for a complete list of the recalled medications.
Last month, the FDA warned consumers against a frequent shortage of drugs for the treatment of high blood pressure because of the recalls. Medications – including valsartan, irbesartan, losartan and others – are known as angiotensin II receptor antagonist medications (ARBs). They are used to treat high blood pressure and heart failure.
FOLLOW ANNOUNCE KNUDSON ON FACEBOOK AND TWITTER.
[ad_2]
Source link